Elamipretide

The specific mechanism of action of SS-31 is described as binding to cardiolipin on the inner mitochondrial membrane. This binding allows mitochondria to heal and recover, reduces reactive oxygen species production, and restores ATP production. This mechanistic description is supported by pre-clinical data referenced by Dr. Yurth.

Dr. Yurth identifies SS-31 (elamipretide/lamipretide) as the highest-impact peptide for muscular dystrophy and mitochondrial dysfunction, describing it as 'the most mechanistically sound peptide' for these conditions. The mechanism involves binding to cardiolipin on the inner mitochondrial membrane, allowing mitochondria to heal, recover, produce fewer reactive oxygen species, and restore ATP production. Pre-clinical (animal) data for muscular dystrophy shows significant benefits. For severe cases, high-dose or even IV administration may be warranted.

The speaker identifies the populations most likely to benefit from SS-31 as those focused on cardiovascular function, physical performance, and cellular energy production. It is also highlighted as particularly relevant for individuals with conditions directly tied to mitochondrial dysfunction. For a general longevity audience, the speaker specifically calls out cardiac and muscular aging data as compelling justifications for its use.

The speaker uses an analogy to explain SS-31's mechanism: the electron transport chain is compared to turbines in a hydroelectric dam, and cardiolipin represents the structural integrity of the dam itself. As cardiolipin degrades with age, the 'turbines' (ETC complexes) misalign and lose efficiency. SS-31 acts as a repair compound that restores structural alignment and returns energy production to full capacity. No dosage information is provided in this segment.

The inner mitochondrial membrane contains a phospholipid called cardiolipin, which plays a critical structural role in the electron transport chain (ETC). With aging, cardiolipin becomes damaged and disorganized, reducing ETC efficiency and dropping energy (ATP) production. SS-31 works by binding directly to cardiolipin, stabilizing it, and restoring the efficiency of the electron transport chain and overall energy production.

The speaker identifies the populations most likely to benefit from SS-31 as those focused on cardiovascular function, physical performance, and cellular energy production, as well as individuals with conditions directly tied to mitochondrial dysfunction. For the broader longevity audience, cardiac and muscular aging data are cited as particularly compelling justifications for use. No specific clinical trials, dosages, or patient numbers are referenced.

The speaker identifies age-related cardiolipin damage and disorganization as a key mechanism underlying mitochondrial dysfunction and declining energy production with aging. This positions SS-31 as a potential intervention against a specific molecular hallmark of mitochondrial aging. The claim is presented as established mechanistic understanding rather than citing a specific study, placing it at the expert-opinion tier. No dosage information is provided.

SS-31 exerts its primary mechanism of action by directly binding to cardiolipin, a phospholipid located on the inner mitochondrial membrane that plays a critical structural role in the electron transport chain (ETC). As mitochondria age, cardiolipin becomes damaged and disorganized, leading to reduced ETC efficiency and declining energy production. SS-31 stabilizes cardiolipin, thereby restoring the structural integrity of the ETC and recovering efficient ATP production. No specific dosage is mentioned in this segment.

SS-31, also known as elamipretide (referred to in the transcript as 'lamopretide'), is a synthetic tetrapeptide — meaning it is composed of four amino acids. It is not naturally produced by the human body but was deliberately engineered to target the inner mitochondrial membrane and improve mitochondrial energy production. The speaker presents this as a designed therapeutic compound rather than a naturally occurring or discovered peptide.

Dr. Yurth frames muscular dystrophy as an extreme, genetically accelerated form of the same mitochondrial dysfunction that underlies age-related sarcopenia and general muscle-building difficulty. The shared pathology includes excessive reactive oxygen species, impaired satellite cell signaling, inability to regenerate muscle, and chronic low-grade inflammation. This framing justifies using the same peptide protocols — particularly SS-31 — across all these patient populations.

Dr. Yurth outlines a comprehensive stacking protocol for patients with muscle-building difficulty, fatigue, muscular dystrophy, or sarcopenia. The core stack includes creatine at 10 grams per day, CoQ10 with geranylgeranyl pyrophosphate (GGPP) for mitochondrial support, SS-31, urolithin A, and exogenous ketones. Peptide adjuncts include growth hormone secretagogues (CJC-1295, ipamorelin, tesamorelin), epitalon, BPC-157, and IGF-1 LR3 for severe cases. She frames this as applicable broadly — not just for muscular dystrophy but for anyone struggling with muscle building or fatigue.

For severe cases of muscular dystrophy or significant muscle loss, Dr. Yurth suggests that high doses of SS-31 (elamipretide) may be necessary, potentially including intravenous (IV) administration. This represents a dosing escalation recommendation beyond standard subcutaneous use, though specific mg or mcg dosages are not provided.

Dr. Yurth outlines a comprehensive stacking protocol for patients with muscular dystrophy, sarcopenia, fatigue, or difficulty building muscle. The core stack includes: creatine at 10 grams per day, CoQ10 with geranylgeranyl pyrophosphate (GGPP) for mitochondrial support, SS-31 (elamipretide), urolithin A, and exogenous ketones. She notes growth hormone secretagogues (CJC, ipamorelin, tesamorelin, ibutamoren) and IGF-1 LR3 as additions for more severe cases, and BPC-157 for angiogenesis and muscle support. This stack is presented as applicable broadly to anyone struggling to build muscle or experiencing fatigue.

SS-31 is described as binding to cardiolipin, the phospholipid layer of the mitochondrial inner membrane that becomes damaged by oxidative stress during burnout. The speaker claims it stabilizes membrane structure, prevents further reactive oxygen species leakage, and reduces new ROS production. A hypothetical dosage of 2 mg every single day is mentioned. The speaker frames this as a targeted intervention for the exact biochemical mechanism of mitochondrial failure.